Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

In addition, the results showed that it has the potential to compete with Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide). Amgen expects its revenue to be between $34.3 billion ...

Despite that assessment, shares in Amgen lost nearly 5% of their value ... better weight loss than Wegovy and roughly in line with Zepbound, which William Blair has now acknowledged is below ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now. By Rebecca Robbins It’s easy to make a medical case for ...

Amgen profits rise, next MariTide studies start ... tap market worth $150 billion Novo Nordisk's Wegovy and Eli Lilly's Zepbound are so far the leaders in the weight-loss drug market, which ...

Amgen’s stock has been rising consistently ... s LLY and Novo Nordisk’s NVO popular GLP-1-based obesity drugs, Zepbound and Wegovy, which are weekly injections.